Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 3Cytokine Release Syndrome 2Schwannomatosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Neurilemmoma 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Immunoglobulin Light-chain Amyloidosis 1Chronic Pain 1Burkitt Lymphoma 1Advanced Malignant Solid Neoplasm 1

Interventions

Cyclophosphamide 103fludarabine 61Methotrexate 49Dexamethasone 46fludarabine phosphate 45Cytarabine 45Vincristine 42blinatumomab 36Whole-Body Irradiation 33Mycophenolic Acid 30Tacrolimus 26Mercaptopurine 26Melphalan 26venetoclax 24Specimen Handling 24Etoposide 23Peripheral Blood Stem Cell Transplantation 21pegaspargase 20Stem Cell Transplantation 19Granulocyte Colony-Stimulating Factor 19Calcium Dobesilate 19Busulfan 19Doxorubicin 18Prednisone 17Rituximab 16Filgrastim 16Daunorubicin 16Asparaginase 16merphos 15Thiotepa 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × siltuximab × 1 year × Clear all
NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

University of Alabama at Birmingham

Phase 2 Completed
24 enrolled 8 charts
LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡